Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92369ArticlesСтатьиResearch ArticleAntagonisty retseptorov angiotenzina II v poiskakh «farmakologicheskoy nishi»Антагонисты рецепторов ангиотензина II в поисках «фармакологической ниши»PerepechN. BПерепечН. БГОУ ВПО Санкт-Петербургская государственная медицинская академия им. И.И.Мечникова1505200795VOL 9, NO5 (2007)ТОМ 9, №5 (2007)364428122021Copyright ©; 2007, Consilium MedicumCopyright ©; 2007, ООО "Консилиум Медикум"2007Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/92369

Прогрессирование сердечно-сосудистых заболеваний – от факторов риска до развития фатальных осложнений – связано с нарастанием активности ренин-ангиотензин-альдостероновой системы (РААС). Хроническая гиперактивация РААС проявляется увеличением содержания в крови и тканях ее главного эффекторного пептида – ангиотензина II. К числу основных физиологических эффектов ангиотензина II относятся вазоконстрикция, усиление синтеза и секреции альдостерона, задержка натрия и воды, повышение тонуса симпатической нервной системы, усиление высвобождения вазопрессина, эндотелина-1 и норадреналина, стимуляция роста кардиомиоцитов и клеток соединительной ткани в миокарде, пролиферации гладкомышечных клеток и фибробластов в сосудистой стенке, а также мезангиальных клеток в почечных клубочках. Повреждающее воздействие ангиотензина II на органы-мишени выражается в развитии гипертрофии миокарда и миокардиофиброза, прогрессировании атеросклероза, повышении внутриклубочкового давления с последующим развитием нефросклероза, патологической цереброваскулярной реконструкции. Результаты выполненных экспериментальных и клинических исследований позволяют считать повышение уровня ангиотензина II независимым фактором риска сердечно-сосудистых заболеваний

Brunner H.R. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001; 87: 3C–9C.Cuspidi C, Muiesan M.L, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Сandesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293–300.Himmelmann A, Keinanen-Kiukaanniemi S, Wester A et al. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Pressure 2001; 10: 43–51.Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 2000; 13: 504–11.Mogensen C.E, Neldam S, Tikkanen I еt al. Randomised controlled trial of dual blockade of renin - angiotensin system in patients with hypertension, microalbuminuria, and non - insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000; 321: 1440–4.Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Pressure 2002; 11: 293–301.Fridman K.U.B, Elmfeldt D, Wysocki M et al. Influence of AT1-receptor blockade on blood pressure, renal hemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients. Blood Pressure 2002; 11: 244–52.Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension. Results of the CARLOS-Study. Clin Drug Invest 2000; 19: 239–46.Pitt B, Pool-Wilson P, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study. Effects of losartan and captopril on mortality and morbidity in high - risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–60.Pfeffer M.A, Mc Murray J.J, Velazquez E.J et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.Mc Kelvie R.S, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056–64.Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995–1003.Malmqvist K, Kahan T, Edner M et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167–76.Mitsunami K, Inoue S, Maeda K et al. Three - month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12: 469–74.Miao C.Y, Xie H.H, Wang J.J, Su D.F. Candesartan inhibits sinoaortic denervation - induced cardiovascular hypertrophy in rats. Acta Pharmacol Sin 2002; 23: 713–20.Jones E.S, Black M.J, Widdop R.E. Angiotensin AT2 receptor contributes to cardiovascular remodeling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol 2004; 37: 1023–30.Isobe N, Taniguchi K, Oschima S et al. Candesartan cilexetil improves left ventricular function in patients with hypertensive heart disease. Circ J 2002; 66: 993–9.Chiadoni L, Virdis A, Magagna A et al. Effect of the angiotensin II type1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertens 2000; 35: 501–6.Horing B, Kohler C, Schlink D et al. AT1-receptor antagonist improves endothelial function in coronary artery disease a bradykinin/B2-receptor - dependent mechanism. Hypertens 2003; 41: 1092–5.Ayoub J.C, Vitola J.V, Parro A.Jr et al. Losartan improves diasolic ventricular filling of hypertensive patients with diastolic dysfunction. Hypertens Res 1999; 22: 155–9.Cuocolo A, Shorto G, Irro R et al. Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril. J Hypertens 1999; 17: 1759–66.Shafer A, Fraccarollo D, Tas P et al. Endothelial dysfunction in congestive heart failure: ACE inhibitors vs. angiotensin II antagonism. Eur J Heart Fail 2004; 6: 151–9.De Gennaro C.V, Fioretti S, Rigamonti A et al. Angiotensin II type 1 receptor antagonism improves endothelial vasodilator function in L-NAME-dependent mechanism. J Hypertens 2006; 24: 95–102.Flynn J.D, Akers W.S. Effects of the angiotensin II subtype 1 receptor antagonist losartan on functional recovery of isolated rat hearts undergoing global myocardial ischemia - reperfusion. Pharmacotherapy 2003; 23: 1401–10.Lange S.A, Wolf B, Schober K et al. Chronic angiotensin II receptor blockade induced cardioprotection during ischemia by increased PKC - epsilon expression in the mouse heart. J Cardiovasc Pharmacol 2007; 49: 46–55.Matsuo K, Kumagai K, Annoura M et al. Effects an angiotensin II antagonist on reperfusion arrhythmias in dogs. Pacing Clin Electrophysiol 1997; 20: 938–45.Hjura N, Wakatsuki T, Yamamoto T et al. Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 2001; 38: 729–36.Patten R.D, Aronovitz M.J, Einstein M et al. Effects of angiotensin II receptor blockade versus angiotensin - converting - enzyme inhibition on ventricular remodeling following myocardial infarction in the mouse. Clin Sci (Lond) 2003; 104: 109–18.Oishi Y, Ozono R, Yoshizumi M et al. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post – myocardial infarction remodeling. Life Sci 2006; 80: 82–8.Preckel B, Schalak W, Gonzalez M et al. Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heart. Basic Res Cardiol 2000; 95: 404–12.Wang O.D, Sjoquist P.O. Effects of the insurmountable angiotensin II AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts. Eur J Pharmacol 1999; 380: 13–21.Xu Y, Menon V, Jugdutt B. Cardioprotection after angiotensin II type 1 blockade involve angiotensin II type 2 receptor expression and activation of protein kinase C-epsilon in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1 and AT2-receptor expression and IP3-receptor and PKC-epsilon proteins. JRAAS 2000; 1: 184–95.Monton M, Jimenez A, Nunrz A et al. Comparative effects of angiotensin II AT1-type receptor antagonists in vitro on human platelet aggregation. J Cardiovasc Pharmacol 2000; 35: 906–13.Li P, Fukuhara M, Diz D.P et al. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A2 – induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 2000; 292: 238–46.Kalinovsky L, Maty S, Chabielska E et al. Angiotensin II AT1 receptor antagonist inhibit platelet adhesion and aggregation by nitric oxide release. Hypertens 2002; 40: 521–7.Brenner B.M, Cooper M.E, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.Lewis E.J, Hunsicker L.G, Clarke W.R et al. Renoprotective effect of angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.Viberti G, Wheedldon N.M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus a blood pressure - independent effect. Circulation 2002; 106: 672–8.Barnett A. Preventing renal complications in diabetic patients: the Diabetic Exposed to Telmisartan And enalaprIL (DETAIL) Study. Acta Diabetol 2005; 42 (Suppl. 11): S42–9.Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Eldery (SCOPE): principal results of a randomized double - blind intervention trial. J Hypertens 2003; 21: 875–86.Schrader J, Luders S, Kulschewski A. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218–26.Schrader J, Luders S, Kulschewski A et al. The ACCESS study. Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699–703.Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimen based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.Lindholm L.H, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive treatment and Lipid Profile In a North of Sweden efficacy Evaluation (ALPINE) study. J Hypertens 2003; 21: 1563–74.Pfeffer M.F, Swedberg K, Granger C.B et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: CHARM - Overall program. Lancet 2003; 362: 759–66.Yusuf S, Ostergren J.B, Gerstein H.S et al. Effect of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112: 48–53.Scheen A.J. Renin - angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta - analysis of randomized clinical trials. Diabetes Metab 2004; 30: 487–96.Berger E.D, Bader B.O, Elbert K et al. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin - converting enzyme inhibition. J Hypertens 2002; 20: 739–43.Cohn J.N, Tognoni G. A randomized trial of the angiotensin - receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–75.